Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 8/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948097 | 0.88 | IL4I1 (0.70) | IL4I1KCNH2CHRM2CHRM4ACHE | |
| SCHEMBL30947966 | 0.88 | IL4I1 (0.67) | IL4I1KCNH2CHRM2CHRM4ACHE | |
| SCHEMBL30948249 | 0.85 | IL4I1 (0.49) | IL4I1CYP11B1CYP11B2 | |
| SCHEMBL30948021 | 0.80 | IL4I1 (0.59) | IL4I1KCNH2LMNAPOLB | |
| SCHEMBL30948371 | 0.79 | IL4I1 (0.61) | IL4I1LMNATHRBPOLB | |
| SCHEMBL27163651 | 0.79 | IL4I1 (0.42) | IL4I1KCNH2CHRM4CYP11B1CYP11B2 | |
| SCHEMBL30948003 | 0.78 | IL4I1 (0.40) | IL4I1THRB | |
| SCHEMBL30948241 | 0.77 | IL4I1 (0.51) | IL4I1KCNH2CHRM2CHRM4ACHE | |
| SCHEMBL30948219 | 0.77 | IL4I1 (0.57) | IL4I1LMNATHRBPOLB | |
| SCHEMBL30948343 | 0.76 | IL4I1 (0.79) | IL4I1KCNH2CHRM2CHRM4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885KCNH2 2998/4885CHRM2 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.